Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
P/B ratio for Alpha Tau Medical Ltd. (DRTS)
P/B ratio as of 2023: 2.46
According to Alpha Tau Medical Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.46. At the end of 2022 the company had a P/B ratio of 1.91.
P/B ratio history for Alpha Tau Medical Ltd. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.46 |
| 2022 | 1.91 |
| 2021 | -11.44 |
| 2020 | -48.45 |
| 2019 | -3538.74 |